107 related articles for article (PubMed ID: 8164052)
1. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer.
Martín M; Lluch A; Casado A; Santabárbara P; Adrover E; Valverde JJ; López-Martín JA; Rodriguez-Lescure A; Azagra P; García-Conde J
J Clin Oncol; 1994 May; 12(5):986-91. PubMed ID: 8164052
[TBL] [Abstract][Full Text] [Related]
2. Preliminary results of a phase II trial of chronic oral etoposide in breast cancer.
Martín M; Casado A; Lluch A; Adrover E; Diaz-Rubio E; García-Conde J
Cancer Treat Rev; 1993; 19 Suppl C():47-52. PubMed ID: 8221716
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin: an active drug in metastatic breast cancer.
Martín M; Díaz-Rubio E; Casado A; Santabárbara P; López Vega JM; Adrover E; Lenaz L
J Clin Oncol; 1992 Mar; 10(3):433-7. PubMed ID: 1740682
[TBL] [Abstract][Full Text] [Related]
4. Oral etoposide monotherapy is effective for metastatic breast cancer with heavy prior therapy.
Yuan P; Xu BH; Wang JY; Ma F; Fan Y; Li Q; Zhang P
Chin Med J (Engl); 2012 Mar; 125(5):775-9. PubMed ID: 22490573
[TBL] [Abstract][Full Text] [Related]
5. Chronic oral etoposide in advanced breast cancer.
Palombo H; Estapé J; Viñolas N; Grau JJ; Mañé JM; Daniels M; Mellado B
Cancer Chemother Pharmacol; 1994; 33(6):527-9. PubMed ID: 8137464
[TBL] [Abstract][Full Text] [Related]
6. Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.
Johnson DH; Greco FA; Strupp J; Hande KR; Hainsworth JD
J Clin Oncol; 1990 Oct; 8(10):1613-7. PubMed ID: 2170589
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacokinetic study of oral etoposide in patients with AIDS-related Kaposi's sarcoma with no prior exposure to cytotoxic therapy.
Schwartsmann G; Sprinz E; Kromfield M; Kalakun L; Sander E; Prolla G; Di Leone L; Gerhardt L; Mans DR
J Clin Oncol; 1997 May; 15(5):2118-24. PubMed ID: 9164226
[TBL] [Abstract][Full Text] [Related]
8. Fractionated doses of oral etoposide in the treatment of patients with aids-related kaposi sarcoma: a clinical and pharmacologic study to improve therapeutic index.
Sprinz E; Caldas AP; Mans DR; Cancela A; DiLeone L; Dalla Costa T; Schwartsmann G
Am J Clin Oncol; 2001 Apr; 24(2):177-84. PubMed ID: 11319295
[TBL] [Abstract][Full Text] [Related]
9. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.
Waits TM; Johnson DH; Hainsworth JD; Hande KR; Thomas M; Greco FA
J Clin Oncol; 1992 Feb; 10(2):292-6. PubMed ID: 1310104
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study.
Gasparini G; Caffo O; Barni S; Frontini L; Testolin A; Guglielmi RB; Ambrosini G
J Clin Oncol; 1994 Oct; 12(10):2094-101. PubMed ID: 7931479
[TBL] [Abstract][Full Text] [Related]
11. Phase II study of oral etoposide for patients with advanced breast cancer.
Atienza DM; Vogel CL; Trock B; Swain SM
Cancer; 1995 Dec; 76(12):2485-90. PubMed ID: 8625074
[TBL] [Abstract][Full Text] [Related]
12. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.
Pusztai L; Walters RS; Valero V; Theriault RL; Hortobagyi GN
Am J Clin Oncol; 1998 Oct; 21(5):442-6. PubMed ID: 9781596
[TBL] [Abstract][Full Text] [Related]
13. Clinical activity of cisplatin and prolonged oral administration of etoposide in previously treated, anthracycline-resistant, metastatic breast cancer patients: a phase II study.
Fried G; Stein ME; Haim N
Med Pediatr Oncol; 2000 Jan; 34(1):10-3. PubMed ID: 10611578
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients.
Valabrega G; Berrino G; Milani A; Aglietta M; Montemurro F
Breast J; 2015; 21(3):241-5. PubMed ID: 25772707
[TBL] [Abstract][Full Text] [Related]
15. Prolonged oral etoposide in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.
Rose PG; Blessing JA; Van Le L; Waggoner S
Gynecol Oncol; 1998 Aug; 70(2):263-6. PubMed ID: 9740702
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of uracil-ftorafur, leucovorin, and etoposide: an active all-oral regimen for metastatic breast cancer.
Hartman AR; Grekowicz A; Lum BL; Carlson RW; Schurman C; Sikic BI; Shapiro R; Stockdale FE
Breast Cancer Res Treat; 2003 Nov; 82(1):61-9. PubMed ID: 14672404
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Feliu J; González Barón M; García-Girón C; Espinosa E; García-Alfonso P; Belón J; Blanco E; Garrido P; Ordónez A; Gómez-Navarro J; Zamora P
Cancer; 1996 Jul; 78(2):211-6. PubMed ID: 8673994
[TBL] [Abstract][Full Text] [Related]
18. Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.
Giannone G; Milani A; Ghisoni E; Genta S; Mittica G; Montemurro F; Valabrega G
Breast; 2018 Apr; 38():160-164. PubMed ID: 29413403
[TBL] [Abstract][Full Text] [Related]
19. Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results.
Calvert AH; Lind MJ; Millward MM; Cantwell BM; Gumbrell L; Proctor M; Simmons D; Chapman F; Robinson A; Charlton C
Cancer Treat Rev; 1993; 19 Suppl C():27-33. PubMed ID: 8221713
[TBL] [Abstract][Full Text] [Related]
20. Salvage therapy with oral etoposide in recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Gedlicka C; Kornfehl J; Turhani D; Burian M; Formanek M
Cancer Invest; 2006; 24(3):242-5. PubMed ID: 16809151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
